Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...
WASHINGTON, DC—Additional evidence, this time from a phase IIb trial in healthy people ages 50 to 80, supports that bentracimab (PhaseBio) provides a near-immediate reversal of ticagrelor’s ...
The coronavirus disease-19 (COVID-19) pandemic that emerged in Wuhan, China, in late December 2019 spread rapidly throughout the world and has caused over 6.5 million deaths. The disease is caused by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback